Late Results of Endovascular Methods of Deep Vein Thrombosis Treatment
- #ES 02-EP-5
- Endovascular Surgery. E-POSTER (ORAL) SESSION-2
- E-Poster (oral)
Late Results of Endovascular Methods of Deep Vein Thrombosis Treatment
Alex Sereditckii 1, Boris Sukovatykh 2, Vadim Muradian 3, Andrey Azarov 3, Michael Sukovatykh 2, Andrey Lapinas 3
1 Orel Regional Hospital, Medical Institute Orel State University I.S.Turgenev, Orel, Russia; 2 Kursk State Medical University, Kursk, Russia; 3 Orel Regional Hospital, Orel, Russia;
Date, time and location: 2018.05.26 13:30, Exhibition area, 1st Floor. Zone – A
Abstract
Materials and methods. An analysis of 93 patients with acute DVT who were treated and investigated using laboratory, ultrasound, and phlebographic methods was carried out. The patients were randomized into three statistically identical groups.
The firs group consisting of 35 (37,6%) patients was treated with a standard start therapy with heparin followed by warfarine administration.
The second group consisting of 34 (36,55%)patients had catheter-guided thrombolysis therapy using Urokinase and had endovascular thrombectomy using Aspirex Straub device. All patients were administered rivaroxabane before and after the treatment.
In the third group consisting of 24 (25,8%)patients had catheter-guided thrombolysis therapy using Urokinase and had endovascular thrombectomy using Aspirex Straub device. Patients were treated with a standard start therapy with heparin and warfarine.Heparin was continued until therapeutic INR (2.-3.0) was achieved.
Dynamic changes were evaluated using ultrasound and phlebographic methods and basing on regress of the clinical syndromes.
Results. In 2 (5,7%) patients during outpatient monitoring was diagnosed recurrent venous thromboembolism. The thromboembolic complications in the second and third groups were not detected. Bleeding complications did not happen in the second group, but were registered in 8 (22,9%) of the first and 3 (12,5%) of the third group patients. Once the therapy had been completed the thrombus was rechanalized in 23 (65,7%) patients of the firs, 26 (76,5%) patients of the second and in 17 (70,7%) of the third group respectively. Chronic venous insufficiency was absent or had a mild presentation in 23 (65,7%) of the firs, 27 (79,4%) of the second and in 18 (75%) of the third group patients respectively.
Conclusion.The combination of the rivaroxabane therapy with endovascular methods in patients with DVT is safe and effective. It reduces clinical presentation of the chronic venous insufficiency and leads to better venous rechanalization of deep veins.